16937446

Source:http://linkedlifedata.com/resource/pubmed/id/16937446

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0021311, umls-concept:C0023895, umls-concept:C0026882, umls-concept:C0030705, umls-concept:C0087111, umls-concept:C0439793, umls-concept:C0524910, umls-concept:C0871261, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C1835407, umls-concept:C2911692
pubmed:issue	29
pubmed:dateCreated	2006-8-28
pubmed:abstractText	To study whether CCR5Delta32 mutation was associated with viral infection and severity of liver disease.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883448
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1007-9327
pubmed:author	pubmed-author:AroraNaveenN, pubmed-author:GoyalAnkurA, pubmed-author:KumarG TGT, pubmed-author:SarinShiv KSK, pubmed-author:ShuklaDeepak KDK, pubmed-author:SuneethaP VPV
pubmed:issnType	Print
pubmed:day	7
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4721-6
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:16937446-Adult, pubmed-meshheading:16937446-Alanine Transaminase, pubmed-meshheading:16937446-Alleles, pubmed-meshheading:16937446-Antiviral Agents, pubmed-meshheading:16937446-Case-Control Studies, pubmed-meshheading:16937446-Disease Progression, pubmed-meshheading:16937446-Drug Therapy, Combination, pubmed-meshheading:16937446-Female, pubmed-meshheading:16937446-Genetic Predisposition to Disease, pubmed-meshheading:16937446-Hepacivirus, pubmed-meshheading:16937446-Hepatitis C, Chronic, pubmed-meshheading:16937446-Humans, pubmed-meshheading:16937446-Interferon-alpha, pubmed-meshheading:16937446-Male, pubmed-meshheading:16937446-Middle Aged, pubmed-meshheading:16937446-Mutation, pubmed-meshheading:16937446-Polyethylene Glycols, pubmed-meshheading:16937446-Receptors, CCR5, pubmed-meshheading:16937446-Recombinant Proteins, pubmed-meshheading:16937446-Ribavirin, pubmed-meshheading:16937446-Severity of Illness Index
pubmed:year	2006
pubmed:articleTitle	CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.
pubmed:affiliation	Department of Gastroenterology, G.B. Pant Hospital, University of Delhi, New Delhi-110002 and Adjunct Professor, Molecular Medicine, Jawaharlal Lal Nehru University, New Delhi, India.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't